

Hospital Acquired Infections Market - 2025

<https://marketpublishers.com/r/H233606C72F7EN.html>

Date: April 2026

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: H233606C72F7EN

Abstracts

The Hospital Acquired Infections Market was valued at USD 16.10 billion in 2025 and is anticipated to reach by , at a CAGR of 0.038 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Hospital Acquired Infections Market.

This report delivers a comprehensive overview of the Hospital Acquired Infections Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hospital Acquired Infections Market. The Hospital Acquired Infections Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–.

Hospital Acquired Infections Market Scope:

By Infection Type

Gastrointestinal Infections

Urinary Tract Infections

Ventilator-Associated Pneumonia

Bloodstream Infections

Surgical Site Infections

Others

By Drug Type

Antibacterial Drug

Antiviral Drug

Antifungal Drug

Others

By End User

Hospitals & ICUs

Ambulatory Surgical & Diagnostic Centers

Nursing Homes & Maternity Centers

Others

Key Players

Merck & Co., Inc.

Pfizer Inc.

AbbVie Inc.

AstraZeneca

GSK plc

Innoviva

ELI LILLY AND COMPANY

STERIS

Cipla Inc.

Basilea Pharmaceutica Ltd.(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Hospital Acquired Infections Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hospital Acquired Infections Market. The Hospital Acquired Infections Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering

in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Infection Type
- 3.2. Snippet by Drug Type
- 3.3. Snippet by End User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. The Rising Clinical Trials by Key Companies
 - 4.1.1.2. Rising Incidence of Hospital-Acquired Infection
 - 4.1.2. Restraints
 - 4.1.2.1. Side Effects Associated with Drugs
 - 4.1.3. Opportunity
 - 4.1.3.1. Rising Regulatory Approvals and Novel Product Launches
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

6. DEMAND-SUPPLY SPECTRUM

- 6.1. Government Initiatives Related to the Market During the Pandemic
- 6.2. Manufacturers' Strategic Initiatives

6.3. Conclusion

7. BY INFECTION TYPE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

7.1.2. Market Attractiveness Index, By Infection Type

7.2. Gastrointestinal Infections *

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Urinary Tract Infections

7.4. Ventilator-Associated Pneumonia

7.5. Bloodstream Infections

7.6. Surgical Site Infections

7.7. Others

8. BY DRUG TYPE

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

8.1.2. Market Attractiveness Index, By Drug Type

8.2. Antibacterial Drug *

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.2.3. Vancomycin

8.2.4. Beta-Lactams

8.2.5. Quinolones

8.2.6. Others

8.3. Antiviral Drug

8.3.1. Acyclovir

8.3.2. Foscarnet

8.4. Antifungal Drug

8.4.1. Amphotericin B

8.4.2. Triazoles

8.5. Others

8.5.1. Antiparasitic

8.5.2. Antiprotozoal

8.5.3. Anti-TB Treatment

9. BY END USER

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

9.1.2. Market Attractiveness Index, By End User

9.2. Hospitals & ICUs *

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Ambulatory Surgical & Diagnostic Centers

9.4. Nursing Homes & Maternity Centers

9.5. Others

10. BY REGION

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.6.1. The U.S.

10.2.6.2. Canada

10.2.6.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.6.1. Germany

10.3.6.2. The U.K.

10.3.6.3. France

10.3.6.4. Spain

10.3.6.5. Italy

10.3.6.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.6.1. Brazil

10.4.6.2. Argentina

10.4.6.3. Rest of South America

10.5. Asia-Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.6.1. China

10.5.6.2. India

10.5.6.3. Japan

10.5.6.4. Australia

10.5.6.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario

11.2. Market Positioning/Share Analysis

11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

12.1. Merck & Co., Inc. *

- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Pfizer Inc.
- 12.3. AbbVie Inc.
- 12.4. AstraZeneca
- 12.5. GSK plc
- 12.6. Innoviva
- 12.7. ELI LILLY AND COMPANY
- 12.8. STERIS
- 12.9. Cipla Inc.
- 12.10. Basilea Pharmaceutica Ltd.(*LIST NOT EXHAUSTIVE)

13. APPENDIX

- 13.1. About Us and Services
- 13.2. Contact Us

I would like to order

Product name: Hospital Acquired Infections Market - 2025

Product link: <https://marketpublishers.com/r/H233606C72F7EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H233606C72F7EN.html>